Stents

Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017

December 13, 2017 — Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug...

The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017

November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting,...

Videos | Stents Bifurcation | November 15, 2017

Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at...

News | Stents | November 10, 2017

November 10, 2017 — Cordis, a Cardinal Health company, recently unveiled a comprehensive...

The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017

November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience...

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017

November 8, 2017 – New results from the HARMONEE Japan/U.S. Registration Trial, reported by in a first report...

Videos | Stents Bioresorbable | November 07, 2017

A discussion with Ajay Kirtane, M.D., SM, director of the cardiac catheterization laboratories at New York-...

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies | November 06, 2017

November 6, 2017 —  The first trial to evaluate the safety of...

Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting | November 06, 2017

November 6, 2017 — Elderly patients undergoing...

Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting | November 03, 2017

November 3, 2017 — Biotronik's Orsiro...

Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting | November 01, 2017

November 1, 2017 — OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at...

Double Kissing Crush Two-Stent Technique in Left Main Bifurcation Lesions Demonstrates Lower Target Lesion Failure Rates
News | Stents Bifurcation | November 01, 2017

November 1, 2017 — The double kissing (DK) crush two-stent technique was associated with a lower rate of target...

Thirty-Day ABSORB IV Results Demonstrate Improvements Still Needed in Bioresorbable Stents
News | Stents Bioresorbable | October 31, 2017

October 31, 2017 – Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting...

FDA Investigating Increased Major Adverse Cardiac Event Rates of Absorb Bioresorbable Stent
News | Stents Bioresorbable | October 31, 2017

October 31, 2017 — The U.S. Food and Drug Administration (FDA) issued a warning to healthcare providers that interim...

FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017

October 27, 2017 — CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved...

Overlay Init